Self-expandable sirolimus-eluting stents compared to second-generation drug-eluting stents for the treatment of the left main: A propensity score analysis from the SPARTA and the FAILS-2 registries.
Volume
93
Pagination
208 - 215
DOI
10.1002/ccd.27809
Journal
Catheter Cardiovasc Interv
Issue
Metadata
Show full item recordAbstract
OBJECTIVES: To compare the effectiveness and safety of self-expandable, sirolimus-eluting Stentys stents (SES) and second-generation drug-eluting stents (DES-II) for the treatment of the unprotected left main (ULM). BACKGROUND: SES may provide a valuable option to treat distal ULM, particularly when significant caliber gaps with side branches are observed. METHODS: Patients from the multicenter SPARTA (clinicaltrials.gov: NCT02784405) and FAILS2 registries were included. Propensity-score with matching was performed to account for the lack of randomization. Primary end-point was the rate of major adverse cardiovascular events (MACE, a composite of all cause death, myocardial infarction, target lesion revascularization [TLR], unstable angina and definite stent thrombosis [ST]). Single components of MACE were the secondary end-points. RESULTS: Overall, 151 patients treated with SES and 1270 with DES-II were included; no differences in MACE rate at 250 days were observed (9.8% vs. 11.5%, P = 0.54). After propensity score with matching, 129 patients treated with SES and 258 with DES-II, of which about a third of female gender, were compared. After a follow-up of 250 days, MACE rate did not differ between the two groups (9.9% vs. 8.5%, P = 0.66), as well as the rate of ULM TLR (1.6% vs. 3.1%, P = 0.36) and definite ST (0.8% vs. 1.2%, P = 0.78). These results were consistent also when controlling for the treatment with provisional vs. 2-stents strategies for the ULM bifurcation. CONCLUSION: SES use for ULM treatment was associated with a similar MACE rate compared to DES-II at an intermediate-term follow-up. SES might represent a potential option in this setting.
Authors
Montefusco, A; D'Ascenzo, F; Gili, S; Smolka, G; Chieffo, A; Baumbach, A; Escaned, J; Sganzerla, P; Tomassini, F; Secco, GGCollections
Language
Related items
Showing items related by title, author, creator and subject.
-
Drug-eluting stents appear superior to bare metal stents for vein-graft PCI in vessels up to a stent diameter of 4 mm.
Guttmann, OP; Jones, DA; Safwan, KA; Gallagher, S; Rathod, KS; Hamshere, S; Smith, EJ; Jain, AK; Mathur, A; Wragg, A (2016-01)BACKGROUND: Research trials have shown improved short-term outcome with drug-eluting stents (DES) over bare metal stents (BMS) in saphenous vein graft (SVG) percutaneous coronary intervention (PCI), primarily by reducing ... -
Comparison of new-generation drug-eluting stents versus drug-coated balloon for in-stent restenosis: a meta-analysis of randomised controlled trials.
Cai, J-Z; Zhu, Y-X; Wang, X-Y; Bourantas, CV; Iqbal, J; Zhu, H; Cummins, P; Dong, S-J; Mathur, A; Zhang, Y-J (2018-02-22)OBJECTIVE: The study sought to compare angiographic and clinical outcomes of new-generation drug-eluting stents (DES) versus drug-coated balloon (DCB) in patients with coronary in-stent restenosis (ISR). DESIGN: Meta-analysis ... -
Magnetically Coated Bioabsorbable Stents for Renormalization of Arterial Vessel Walls after Stent Implantation
Lee, JS; Hang, P; Sone, E; Kim, D; Lee, H; Labowsky, M; Taavitsainen, J; Yla-Herttuala, S; Hytonen, J; Guelcher, M (2018-01)